Clinical application and drug-use-guidance value of metagenomic next-generation sequencing in central nervous system infection

Ke Lin; Hao-Cheng Zhang; Yi Zhang; Yang Zhou; Zhang-Fan Fu; Hong-Yu Wang; Yuan-Han Zhao; Chao Qiu; Ming-Xiang Fan; Jie-Yu Song; Jing-Wen Ai; Wen-Hong Zhang

Clinical application and drug-use-guidance value of metagenomic next-generation sequencing in central nervous system infection

Am J Transl Res. 2023 Jan 15;15(1):47-62. eCollection 2023.

Authors

Ke Lin¹, Hao-Cheng Zhang¹, Yi Zhang¹, Yang Zhou¹, Zhang-Fan Fu¹, Hong-Yu Wang¹, Yuan-Han Zhao¹, Chao Qiu^{1

2}, Ming-Xiang Fan³, Jie-Yu Song¹, Jing-Wen Ai¹, Wen-Hong Zhang^{1

2

4

5}

Affiliations

¹ Department of Infectious Disease of Huashan Hospital, National Medical Center for Infectious Diseases and Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Fudan University Shanghai 200040, China.
² Key Laboratory of Medical Molecular Virology (MOE/MOH) and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University Shanghai 200032, China.
³ Department of Urology, Tongji Hospital, School of Medicine, Tongji University Shanghai 200065, China.
⁴ State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University Shanghai 200438, China.
⁵ National Clinical Research Centre for Aging & Medicine, Huashan Hospital, Fudan University Shanghai 200040, China.

PMID: 36777850
PMCID: PMC9908477

Abstract

Objective: Timely and precise etiology diagnosis is crucial for optimized medication regimens and better prognosis in central nervous system infections (CNS infections). We aimed to analyze the impact of mNGS tests on the management of patients with CNS infections.

Methods: We conducted a single-center retrospective cohort study to analyze the value of mNGS in clinical applications. Three hundred sixty-nine patients with a CNS infection diagnosis were enrolled, and their clinical data were collected. CDI and DDI were defined in our study to describe the intensity of drug use in different groups. We used LOH and mRS to evaluate if the application of mNGS can benefit CNS infected patients.

Results: mNGS reported a 91.67% sensitivity in culture-positive patients and an 88.24% specificity compared with the final diagnoses. Patients who participated with the mNGS test had less drug use, both total (58.77 vs. 81.18) and daily (22.6 vs. 28.12, P < 0.1, McNemar) intensity of drug use, and length of hospitalization (23.14 vs. 24.29). Patients with a consciousness grading 1 and 3 had a decrease in CDI (Grade 1, 86.49 vs. 173.37; Grade 3, 48.18 vs. 68.21), DDI (Grade 1, 1.52 vs. 2.72; Grade 3, 2.3 vs. 2.45), and LOH (Grade 1, 32 vs. 40; Grade 3, 21 vs. 23) with the application of mNGS. Patients infected with bacteria in the CNS had a reduced CDI, DDI, and LOH in the mNGS group. This was compared with the TraE group that had 49% of patients altered medication plans, and 24.7% of patients reduced drug intensity four days after mNGS reports. This was because of the reduction of drug types.

Conclusion: mNGS showed its high sensitivity and specificity characteristics. mNGS may assist clinicians with more rational medication regimens and reduce the drug intensity for patients. The primary way of achieving this is to reduce the variety of drugs, especially for severe patients and bacterial infections. mNGS has the ability of improving the prognosis of CNS infected patients.

Keywords: Metagenomic next-generation sequencing; central nervous system infection; diagnose; drug intensity; prognosis.